RU2142274C1 - Агент для лечения состояния тревоги - Google Patents

Агент для лечения состояния тревоги Download PDF

Info

Publication number
RU2142274C1
RU2142274C1 RU94034109A RU94034109A RU2142274C1 RU 2142274 C1 RU2142274 C1 RU 2142274C1 RU 94034109 A RU94034109 A RU 94034109A RU 94034109 A RU94034109 A RU 94034109A RU 2142274 C1 RU2142274 C1 RU 2142274C1
Authority
RU
Russia
Prior art keywords
anxiety
compound
animals
test
oxo
Prior art date
Application number
RU94034109A
Other languages
English (en)
Russian (ru)
Other versions
RU94034109A (ru
Inventor
Вульферт Эрнст
Гобер Жан
Гауэр Алма
Коссеман Эрик
Original Assignee
Юцб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юцб filed Critical Юцб
Publication of RU94034109A publication Critical patent/RU94034109A/ru
Application granted granted Critical
Publication of RU2142274C1 publication Critical patent/RU2142274C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
RU94034109A 1993-09-24 1994-09-23 Агент для лечения состояния тревоги RU2142274C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9319732.5 1993-09-24
GB939319732A GB9319732D0 (en) 1993-09-24 1993-09-24 Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety

Publications (2)

Publication Number Publication Date
RU94034109A RU94034109A (ru) 1997-12-10
RU2142274C1 true RU2142274C1 (ru) 1999-12-10

Family

ID=10742476

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94034109A RU2142274C1 (ru) 1993-09-24 1994-09-23 Агент для лечения состояния тревоги

Country Status (17)

Country Link
US (1) US5447952A (https=)
EP (1) EP0645139B1 (https=)
JP (1) JP3688735B2 (https=)
KR (1) KR950007848A (https=)
AT (1) ATE191849T1 (https=)
AU (1) AU672334B2 (https=)
CA (1) CA2132509A1 (https=)
DE (1) DE69424009T2 (https=)
ES (1) ES2145818T3 (https=)
GB (1) GB9319732D0 (https=)
HU (1) HU217124B (https=)
NO (1) NO943521L (https=)
NZ (1) NZ264506A (https=)
RU (1) RU2142274C1 (https=)
SG (1) SG86284A1 (https=)
TW (1) TW283642B (https=)
ZA (1) ZA947444B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525347A (en) * 1995-01-31 1996-06-11 Medical University Of South Carolina Composition and methods for treating performance anxiety
CA2475026A1 (en) 1999-12-01 2001-06-07 Ucb, S.A. A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
WO2007086891A1 (en) * 2006-01-24 2007-08-02 Teva Pharmaceutical Industries Ltd. Levetiracetam formulations and methods for their manufacture
US20090082394A1 (en) * 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
WO2008021666A2 (en) * 2006-08-18 2008-02-21 Morton Grove Pharmaceuticals, Inc. Stable liquid levetiracetam compositions and methods
ATE524466T1 (de) * 2007-07-03 2011-09-15 Actelion Pharmaceuticals Ltd 3-azabicycloä3.3.0üoktanverbindungen
KR20100046047A (ko) * 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
DK3260118T3 (da) 2008-10-16 2021-04-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
US8191547B2 (en) * 2008-10-23 2012-06-05 S-2Tech Llc Portable solar-heating system having an inflatable solar collector
US20100172979A1 (en) * 2008-12-24 2010-07-08 Zhongshui Yu Controlled-release formulations
US20100159009A1 (en) * 2008-12-24 2010-06-24 Zhongshui Yu Controlled-release formulations
EA202092673A3 (ru) * 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
BR112013020283A2 (pt) * 2011-02-09 2016-07-19 Univ Johns Hopkins "uso de inibidor de proteína de vesícula sináptica 2a (sv2a), valproato, levetiracetam, brivarecetam e seletracetam no tratamento de deficiência cognitiva, bem como composição farmacêutica compreendendo os mesmos"
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
SG11202105863PA (en) * 2018-12-04 2021-07-29 Metys Pharmaceuticals AG Synergistic compositions comprising (r)-2-(2-oxopyrrolidin-1-yl)butanamide and (s)-2-(2-oxopyrrolidin-1-yl)butanamide in a non-racemic ratio

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162036A1 (fr) * 1984-05-15 1985-11-21 U C B, S.A. (S)-alpha-éthyl-2-oxo-1-pyrrolidineacétamide
SU1320707A1 (ru) * 1985-01-24 1987-06-30 Ивано-Франковский Институт Нефти И Газа Способ определени износостойкости материалов ма тниковым склерометром
SU1414845A1 (ru) * 1984-03-23 1988-08-07 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе 1-Тиокарбамоилметилпирролидин-2-тион,обладающий ноотропной активностью, и способ его получени
EP0408782A1 (en) * 1989-07-18 1991-01-23 Nauchnoissledovatelski Chimikopharmatzevtichen Institut Antihypoxic agent
US5143912A (en) * 1990-08-21 1992-09-01 Hoffmann-La Roche, Inc. Tricyclic pyridone derivatives

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8827389D0 (en) 1988-11-23 1988-12-29 Ucb Sa Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1414845A1 (ru) * 1984-03-23 1988-08-07 Всесоюзный Научно-Исследовательский Химико-Фармацевтический Институт Им.С.Орджоникидзе 1-Тиокарбамоилметилпирролидин-2-тион,обладающий ноотропной активностью, и способ его получени
EP0162036A1 (fr) * 1984-05-15 1985-11-21 U C B, S.A. (S)-alpha-éthyl-2-oxo-1-pyrrolidineacétamide
SU1320707A1 (ru) * 1985-01-24 1987-06-30 Ивано-Франковский Институт Нефти И Газа Способ определени износостойкости материалов ма тниковым склерометром
EP0408782A1 (en) * 1989-07-18 1991-01-23 Nauchnoissledovatelski Chimikopharmatzevtichen Institut Antihypoxic agent
US5143912A (en) * 1990-08-21 1992-09-01 Hoffmann-La Roche, Inc. Tricyclic pyridone derivatives

Also Published As

Publication number Publication date
AU7416994A (en) 1995-04-06
ATE191849T1 (de) 2000-05-15
SG86284A1 (en) 2002-02-19
HU217124B (hu) 1999-11-29
NO943521D0 (no) 1994-09-22
ZA947444B (en) 1995-05-11
KR950007848A (ko) 1995-04-15
US5447952A (en) 1995-09-05
DE69424009T2 (de) 2000-09-14
EP0645139A1 (fr) 1995-03-29
DE69424009D1 (de) 2000-05-25
ES2145818T3 (es) 2000-07-16
CA2132509A1 (en) 1995-03-25
HUT68299A (en) 1995-06-28
NZ264506A (en) 1997-09-22
NO943521L (no) 1995-03-27
JPH07149639A (ja) 1995-06-13
AU672334B2 (en) 1996-09-26
TW283642B (https=) 1996-08-21
EP0645139B1 (fr) 2000-04-19
GB9319732D0 (en) 1993-11-10
JP3688735B2 (ja) 2005-08-31

Similar Documents

Publication Publication Date Title
RU2142274C1 (ru) Агент для лечения состояния тревоги
RU2338533C1 (ru) СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
Šlamberová Drugs in pregnancy: the effects on mother and her progeny.
Kosofsky et al. Transplacental cocaine exposure: a mouse model demonstrating neuroanatomic and behavioral abnormalities
EP2533645B1 (en) Methods and compositions for improving cognitive function
NZ238277A (en) Veterinary agent for retarding age-dependent deterioration comprising 1-deprenyl
US11160785B2 (en) Methods and compositions for improving cognitive function
Craig et al. Long-term behavioral effects in a rat model of prolonged postnatal morphine exposure.
JPH09501908A (ja) 穏和不安緩解薬および穏和鎮静薬としてのイソバレラマイドの使用
KR100346883B1 (ko) 만성폐색성동맥경화증의치료에유용한카르니틴유도체-함유약제
Heyser et al. Effects of prenatal exposure to cocaine on Morris water maze performance in adult rats.
Pauli et al. Spatial learning ability of rats following acute exposure to alcohol during early postnatal life
RU2025124C1 (ru) Антистрессорное, стресспротекторное, ноотропное средство, способ профилактики и лечения стрессовых состояний и способ повышения умственной работоспособности
ES2314458T3 (es) Uso de un derivado de haluro de acido hidroximico para el tratamiento de enfermedades neurodegenerativas.
US10272080B2 (en) Selective dopamine D4 receptor agonists for treatment of working memory deficits
US20070259865A1 (en) Agent for Promoting the Recovery from Dysfunction After the Onset of Central Neurological Disease
Jones et al. Effect of amantadine on the urinary excretion of some monoamines and metabolites in normal and Parkinsonian subjects
Asano et al. Effects of methamphetamine on daily rhythms of hypothalamic norepinephrine, serotonin and plasma corticosterone levels in the rat
EP1942891B1 (en) Novel combination of drugs as antidepressant
Pan et al. Evaluation of acute tacrine treatment on passive-avoidance response, open-field behavior, and toxicity in 17-and 30-day-old mice
WO2012094949A1 (zh) 依托咪酯在制备预防或治疗创伤后应激障碍药物中的应用
RU2546300C1 (ru) Композиция, обладающая действием на центральную нервную систему и ее применение
CN117919243A (zh) 荷叶碱治疗改善认知障碍、脑萎缩、神经细损伤的新用途
Manasa Experimental Evaluation of Anticonvulsant Activity of Hydrocotyle Asiatica Linn (Centella Asiatica) in Albino Mice
Ellenbroek Early life stressors and late life consequences as animal models for schizophrenia